



19th February 2010

Opto Circuits India's European subsidiary, Eurocor GmbH, recently had the distinction of its marquee CE-marked product – DIOR: The Paclitaxel coated Coronary Balloon Dilatation Catheter, being the first drug eluting balloon to be used in Canada. Dr. Olivier Bertrand used the special access program from Santé Canada to successfully perform an angioplasty using DIOR.

The data from these procedures will be included in the Valentines Trial that started on Sunday, February 14th (Valentines day), 2010 and is a unique first of its kind multi-centre, open-label registry of patients suffering from in-stent restenosis (ISR). 248 sites from 31 countries around the globe committed to include cases to this unique exercise. The Trial will run up to 23rd February, the end of the CRT Congress in Washington, DC of which Dr. Ron Waksman is the Chairman. Dr. Olivier Bertrand and Dr. Rembert Pogge von Strandmann (clinical director Eurocor) are invited to deliver lectures on DIOR on the 2nd day of the Congress.

DIOR is a drug eluting balloon which can be used safely in patients with In-Stent Restenosis, Bifurcation lesions and lesions in Small vessels. For more information, please visit:

http://www.eurocor.de/products/dior/product_information/

About Eurocor GmbH

Eurocor is a technology leader in cardiovascular medical devices. Its innovative product developments position Eurocor as a growing force in minimally invasive medicine. Opto Circuits India acquired Eurocor in 2006.

Note: Please write to us at ir@optoindia.com if you wish to attend the lecture by Dr. Olivier Bertrand and Dr. Rembert Pogge on DIOR at CRT, Washington, DC on 22nd February; our colleagues at the conference will be happy to assist you at the venue.